Buyback Spend for Bristol-Myers Squibb (BMY)
Buyback Spend for Bristol-Myers Squibb (BMY): headline value $0. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingBuyback SpendSwitch metric
Latest period
$0
YoY change
N/A
5Y CAGR
-100.0%
Peak year (2022)
$8.00B
Latest annual
$0
Buyback Spend history chart for Bristol-Myers Squibb (BMY) from 1989 to 2025
Buyback Spend history table for Bristol-Myers Squibb (BMY) from 1989 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $0 | — | ||
| 2024 | $0 | -100.0% | ||
| 2023 | $5.16B | -35.6% | ||
| 2022 | $8.00B | +27.3% | ||
| 2021 | $6.29B | +306.7% | ||
| 2020 | $1.55B | -78.8% | ||
| 2019 | $7.30B | +2181.3% | ||
| 2018 | $320.00M | -87.0% | ||
| 2017 | $2.47B | +968.8% | ||
| 2016 | $231.00M | — | ||
| 2015 | $0 | — | ||
| 2014 | $0 | -100.0% | ||
| 2013 | $433.00M | -82.0% | ||
| 2012 | $2.40B | +96.8% | ||
| 2011 | $1.22B | +112.0% | ||
| 2010 | $576.00M | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | -100.0% | ||
| 2002 | $164.00M | -89.7% | ||
| 2001 | $1.59B | -32.0% | ||
| 2000 | $2.34B | +64.8% | ||
| 1999 | $1.42B | -9.1% | ||
| 1998 | $1.56B | +34.3% | ||
| 1997 | $1.16B | +36.4% | ||
| 1996 | $852.00M | +249.2% | ||
| 1995 | $244.00M | -65.2% | ||
| 1994 | $701.00M | +67.3% | ||
| 1993 | $419.00M | +83.8% | ||
| 1992 | $228.00M | -49.0% | ||
| 1991 | $447.00M | -20.5% | ||
| 1990 | $562.00M | +1002.0% | ||
| 1989 | $51.00M | — |
Buyback Spend values are taken from Bristol-Myers Squibb's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported buyback spend of $0.
Through 2020–2025 (5 years), Bristol-Myers Squibb buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Bristol-Myers Squibb buyback spend peaked at $8.00B in 2022; the latest annual figure is $0 in 2025 (100.0% below peak).
The highest annual buyback spend of $8.00B was reported in 2022. The lowest in the available history was $0 in 2003.
Bristol-Myers Squibb (BMY) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Bristol-Myers Squibb Buyback Spend by Year
Bristol-Myers Squibb Buyback Spend 2025: $0
Bristol-Myers Squibb buyback spend in 2025 was $0.
Bristol-Myers Squibb Buyback Spend 2024: $0
Bristol-Myers Squibb buyback spend in 2024 was $0, plunged 100.0% below 2023.
Bristol-Myers Squibb Buyback Spend 2023: $5.16B
Bristol-Myers Squibb buyback spend in 2023 was $5.16B, plunged 35.6% below 2022.
Bristol-Myers Squibb Buyback Spend 2022: $8.00B
Bristol-Myers Squibb buyback spend in 2022 was $8.00B, grew 27.3% from 2021. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Buyback Spend 2021: $6.29B
Bristol-Myers Squibb buyback spend in 2021 was $6.29B.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers — Buyback Spend
Companies in the same sector as Bristol-Myers Squibb, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Novo Nordisk A/S (NVO) | $1.39B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Bristol-Myers Squibb's buyback spend?
Latest reported buyback spend for Bristol-Myers Squibb (BMY) is $0 (period ending December 31, 2025).
What is the long-term growth rate of Bristol-Myers Squibb buyback spend?
Bristol-Myers Squibb (BMY) buyback spend compound annual growth rate is -100.0% over the most recent 5 years available.
When did Bristol-Myers Squibb buyback spend hit its highest annual value?
Bristol-Myers Squibb buyback spend reached its highest annual value of $8.00B in 2022.
What was Bristol-Myers Squibb buyback spend in 2024?
Bristol-Myers Squibb (BMY) buyback spend in 2024 was $0.
What was Bristol-Myers Squibb buyback spend in 2025?
Bristol-Myers Squibb (BMY) buyback spend in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
BMY Overview
Company profile, financial tools, and key metrics
BMY Revenue Counter
Earns $1,528 every second. See per minute, hour, and day.
BMY Earnings Counter
Earns $223.65 per second net profit. See per minute, hour, and day.
BMY Economic Scale
Exceeds Bahrain's GDP. Compare with world economies.
BMY What If Invested
What if you had invested $1,000? See historical returns from any date.
BMY How It Makes Money
Discover visual breakdown of $48.19B in revenue — where it comes from and where it goes.
BMY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BMY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BMY Daily Price Character
Steady · 47.3% historical win rate (green days). Streaks & record days.
BMY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BMY Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
BMY Dividend Profile
Yield: 4.34%. Safety: 7/8. See full history.
BMY Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
BMY Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.